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Adoptive T-cell immunotherapy for ganciclovir-resistant
CMV disease after lung transplantation
Chien-Li Holmes-Liew1,2, Mark Holmes1,2, Leone Beagley3, Peter Hopkins4,5, Daniel Chambers4,5, Corey Smith3
and Rajiv Khanna3
Infections with cytomegalovirus (CMV) can induce severe complications after solid organ transplantation (SOT). The prognosis for
ganciclovir-resistant CMV infection and disease is particularly poor. Whereas adoptive transfer of CMV-speciﬁc T cells has
emerged as a powerful tool in hematopoietic stem cell transplant patients, its translation into the SOT setting remains a
signiﬁcant challenge as underlying immunosuppression inhibits the virus-speciﬁc T-cell response in vivo. Here, we demonstrate
successful expansion and adoptive transfer of autologous CMV-speciﬁc T cells from a seronegative recipient of a seropositive
lung allograft with ganciclovir-resistant CMV disease, resulting in the long-term reconstitution of protective anti-viral immunity,
CMV infection, disease-free survival and no allograft rejection.
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The incidence of symptomatic cytomegalovirus (CMV) disease
following solid organ transplantation (SOT) has decreased with the
advent of ganciclovir, the mainstay of prophylactic, pre-emptive and
treatment strategies.1,2 However, ganciclovir-resistant CMV (GRCMV)
disease poses major treatment difﬁculties, with signiﬁcant morbidity
and mortality due to end-organ effects and immunomodulation
leading to bronchiolitis obliterans syndrome (BOS) and allograft
loss.3–5 The incidence in lung transplant (LTx) recipients is up to
9%, the highest of any SOT,6,7 with up to 17.6% of viraemic lung
transplant recipients demonstrating resistance compared with 6.2% of
viraemic renal transplant patients.8 Management includes cautious
reduction in immunosuppression to allow immune reconstitution and
activity against CMV,7 but this confers a risk of lung allograft
rejection.9 Alternative treatments are limited: foscarnet is the ﬁrst-
line for the treatment of GRCMV.10 Although some patients treated
with foscarnet have been shown to improve, the major problem in
lung transplant recipients is signiﬁcant nephrotoxicity.7 In addition,
intravenous treatment is required, often with pre-hydration and
reduction of other potentially nephrotoxic medications. This limits
long-term use in treating and preventing recurrent disease. A further
alternative, cidofovir, has no controlled studies but this agent is also
highly nephrotoxic.7,11,12 Prognosis following GRCMV disease is
therefore poor, with crude mortality ranging from 19 to 100%.1,8
The study by Mitsani et al.1 reported 100% mortality as a direct result
of CMV disease in four patients infected with GRCMV, despite the use
of aggressive anti-viral regimens that included various combinations of
foscarnet, cidofovir and CMV intravenous immunoglobulin (IVIg).
These regimens are associated with signiﬁcant toxicities and expense.6
Therefore, alternative effective therapeutic options are urgently
required.
Immunologic control of CMV is complex and T-cell responses are
critical. T-cell reactivity is directed towards a wide range of CMV
antigens, and natural killer cells typically increase in response to viral
replication.13,14 Adoptive transfer of CMV-speciﬁc T-cell lines demon-
strates promising results in hematopoietic stem cell transplantation
(HSCT) recipients.15,16 However, generation of speciﬁc T-cell lines
ex vivo and their function in vivo is more complicated in SOT
recipients and success has not been achieved previously—a single case
report describes generation of CMV-speciﬁc T-cell lines from a patient
with GRCMV disease, however the patient did not survive long term.
17 In HSCT, peripheral blood mononuclear cells (PBMCs) taken as
starting material for CMV-speciﬁc T-cell generation are derived from
healthy donors. In SOT, starting material must be recovered from
immunosuppressed patients for autologous use.17 Following LTx,
CMV disease is mainly due to seronegative recipients receiving
seropositive donor organs, in contrast to post HSCT, when the
majority is due to reactivation. Here, we present a case of successful
adoptive transfer of autologous CMV-speciﬁc T cells to a LTx
recipient with ganciclovir-resistant tissue-invasive CMV disease,
resulting in uncomplicated long-term survival.
CASE REPORT
A 41-year-old female (human leucocyte antigen (HLA)-A1, -A11, -B7,
-B35, -Cw4, -Cw7, -DR1 and -DR14) received CMV mismatched
(D+/R− ) bilateral sequential LTx in June 2012 for cystic ﬁbrosis.
Immunosuppression was tacrolimus, prednisolone and azathioprine.
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CMV prophylaxis was CMV hyperimmune globulin and ganciclovir,
followed by continuous valganciclovir 450mg twice daily. The patient
had mild renal impairment (estimated glomerular ﬁltration rate of
46ml min− 1). Three months post transplant, she developed an
asymptomatic increase in blood CMV PCR (DNAemia: 2769 DNA
copies ml− 1; Figure 1), new onset pancytopaenia (haemoglobin 97
g l− 1, white cell count 3.64× 109 l− 1, platelets 140× 109 l− 1) and liver
dysfunction (gamma glutamyl transferase (GGT) 175, alkaline phos-
phatase (ALP) 134, alanine aminotransferase (ALT) 79 and aspartate
aminotransferase (AST) 69U l− 1) consistent with hepatitis. Despite
intravenous ganciclovir and CMV hyperimmune globulin, the blood
CMV PCR continued to rise. CMV PCR was also detected in
bronchoalveolar lavage (BAL) ﬂuid during bronchoscopy. Foscarnet
was commenced. Leukopenia was minimised by cessation of
azathioprine and trimethoprim/sulfamethoxazole. Tacrolimus was
changed to everolimus and leﬂunomide added. CMV PCR peaked at
344 386 DNA copiesml− 1 on day 18 post ganciclovir commencement
(Figure 1). CMV gene results conﬁrmed UL97 gene mutation L595S
conferring ganciclovir resistance. Foscarnet was continued. Resolution
of the pancytopaenia and hepatic dysfunction occurred, while CMV
PCR ﬂuctuated and gradually reduced to undetectable levels after
6 weeks of continuous treatment with foscarnet and reduced
immunosuppression. Surveillance transbronchial biopsies showed
mild (A2) acute cellular rejection, treated with methylprednisolone
and oral steroids and fortnightly IVIg. After 2 weeks of undetectable
CMV PCR levels, foscarnet was ceased. Two weeks later, the patient
had another asymptomatic rise in CMV PCR (2059 DNA copies-
ml− 1) requiring a further 2 weeks of foscarnet, which reduced the
CMV PCR back to undetectable (Figure 1). The patient continued
IVIg fortnightly until T-cell therapy was commenced 5 months after
the initial presentation.
TREATMENT
We obtained approval from the ethics committee to expand and infuse
autologous CMV-speciﬁc T cells generated from the patient as
outlined in the Methods section below. On the basis of the HLA type
of the patient, CMV-speciﬁc immunodominant peptide epitopes were
selected for T-cell expansion.18 A total of 12× 107 T cells were
expanded and equally divided into four vials. The dose selected per vial
was based upon the total number of cells that were manufactured.
Phenotypic analysis showed that the expanded cells were predomi-
nantly T cells CD3+ (82.6%), including both CD8+ (73.8%) and CD4+
(14%) T cells. T cells speciﬁc for all of the peptide epitopes used in the
study could be detected following expansion. Analysis using an
intracellular interferon (IFN)-γ assay revealed an increase in the
proportion of CMV-speciﬁc T cells directed towards the HLA-A1-
restricted VTEHDTLLY (5.35%), HLA-A1-restricted YSEHPTFTSQY
(2.26%), HLA-B7-restricted TPRVTGGGAM (2.91%), HLA-B7-
restricted RPHERNGFTVL (0.46%), HLA-B35-restricted FPTKDVAL
(0.35%), and HLA-B35-restricted IPSINVHHY (0.35%) peptide
epitopes. Representative data from the dominant pp50 encoded,
VTEHDTLLY (referred to as VTE) and the pp65 encoded epitope,
TPRVTGGGAM (referred to as TPR) are shown in Figure 2a. These
in vitro expanded T cells also displayed an increase in cytolytic
potential, characterised by an increase in the proportion of IFN-γ
































































































































































































































































































































































Figure 1 CMV replication before and after adoptive T-cell therapy. Timeline of viral replication as detected by a qualitative assay for CMV PCR in relation to
anti-viral therapy and autologous adoptive T-cell transfer. The speciﬁc time point of detection of the UL97 mutation is also indicated in the graph.
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The patient received four infusions of autologous adoptive T-cell
immunotherapy. No adverse events occurred. Ex vivo virus-speciﬁc
T-cell immunity in the peripheral blood was monitored using MHC-
multimer analysis, surface receptor phenotyping and polyfunctional
cytokine analysis. Althogh there was an increase in the frequency of
pp65-speciﬁc T cells in the peripheral blood, pp50-speciﬁc T-cell
numbers decreased following the completion of adoptive immu-
notherapy. Ex vivo surface phenotypic analyses revealed a reduction
in the proportion of CD57+ and PD1+ pp65-speciﬁc T cells post
infusion, but no change in pp50-speciﬁc T cells (Figure 2c). However,
intracellular cytokine analyses showed that both pp65 and pp50-
speciﬁc T-cells displayed an increased proportion of IFN-γ+CD107a+
T cells during and post infusion (Figure 2d).
The patient’s usual immunosuppression regime was resumed and
CMV PCR remained negative in plasma, BAL and transbronchial
biopsies for 16 months, at which point an asymptomatic increase in
CMV PCR occurred. This became undetectable rapidly with no
medical intervention or alteration in treatment. At 20 months post
treatment, the CMV PCR remains undetectable, hepatic and bone
marrow function remains normal and there has been no evidence of
acute rejection on transbronchial biopsies, or BOS on serial lung
function measurements.
COMMENT
In this report, we describe the successful treatment of primary and
persistent GRCMV infection post LTx using adoptive T-cell immu-
notherapy. After persistently elevated blood CMV PCR levels, evidence
of hepatitis as end-organ disease despite prolonged treatment with
foscarnet and recurrence of detectable PCR when foscarnet was ceased
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Figure 2 Functional characterisation of CMV-speciﬁc T cells. (a) PBMC and in vitro expanded T cells were stimulated for 5 h with cognate peptide in the
presence of brefeldin A, then assessed for IFN-γ expression. Data presented in each subpanel indicates the percentage of peptide-speciﬁc T cells producing
IFN-γ. (b) PBMC and in vitro expanded T cells were stimulated for 5 h with cognate peptide in the presence of brefeldin A and monensin, then assessed for
IFN-γ expression and degranulation using surface CD107a expression. Data in each pie chart represents the proportion of VTE or TPR speciﬁc T cells
expressing CD107a and IFN-γ (blue) CD107a alone (red) or IFN-γ alone (yellow). (c) PBMC were labelled with the HLA-B7/TPR (pp65) or HLA-A1/VTE
(pp50) dextramer then assessed for surface expression of CD27, CD45RA, CD57 and PD1. Data in the left sub-panels represents the frequency of TPR
(pp65) or VTE (pp50)-speciﬁc CD8+ T cells. Data in the right sub-panels represents the proportion of TPR- or VTE-speciﬁc CD8+ T cells expressing each
phenotypic marker. (d) PBMC were stimulated for 5 h with TPR (pp65) or VTE (pp50) peptide in the presence of brefeldin A and monensin, then assessed
for IFN-γ expression and degranulation using surface CD107a expression.
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negative and has remained controlled for 20 months post-T-cell
therapy, without any other pharmacological treatment, while on
standard immunosuppression. Other treatment options were unac-
ceptable: foscarnet was not feasible for long term due to renal
impairment. Without adequate control of CMV infection, long-term
reduced immunosuppression would have been required, potentially
leading to further episodes of acute rejection, reduced allograft
function and worse survival. Were the patient to survive, high medical
costs and poor quality of life would ensue.
To date, there are few reports of adoptive T-cell immunotherapy for
treatment of ganciclovir-resistant CMV infection or disease following
SOT. In the only report following LTx,17 CMV disease responded to
immunotherapy initially but recurred after 4 weeks and viral load
stayed despite a second infusion of CMV-speciﬁc T cells. After 6 weeks,
the patient developed cellular rejection and was treated with steroids,
leading to an increase in peripheral CMV viral load. The patient died
from histologically proven graft failure 2 weeks later. It is not clear
why the transferred T cells did not totally clear the virus from the
blood, and it was not possible to exclude an association between
rejection and the T-cell application, and high caution was recom-
mended. Our experience shows that established CMV infection can be
cleared, and demonstrates success in utilisation of adoptive T-cell
immunotherapy to treat GRCMV disease post LTx, in the presence of
immunosuppression, without complications. Although it is possible
that partial immune restoration may have also contributed towards
viral control, the improved cytolytic potential in both pp65- and pp50-
speciﬁc T cells following infusion suggests that adoptive therapy may
have contributed to the improved immune control of CMV. Although
four doses of T cells were administered, evidence of persistent viral
reactivation was not evident following administration of the ﬁrst vial,
suggesting that a single dose of T cells may have been adequate to
control infection. In addition, the persistent episodes of relapse before
therapy and cessation of episodes immediately following treatment, as
well as control of a late asymptomatic rise in CMV PCR without anti-
CMV treatment shows that the patient achieved stable immune
reconstitution which was able to control the viral reactivation,
representing proof of concept for T-cell immunotherapy. The data
are relevant beyond this case, highlighting the exciting potential of this
approach as a new treatment option where no adequate treatment
strategies previously existed. Future research will focus on developing
the therapy for larger patient numbers.
METHODS
Generation of CMV-speciﬁc T cells for adoptive immunotherapy
To expand CMV-speciﬁc T cells, PBMC were stimulated with
autologous PBMC coated with HLA class I-restricted CMV peptide
epitopes VTEHDTLLY, YSEHPTFTSQY, TPRVTGGGAM,
RPHERNGFTVL, FPTKDVAL, and IPSINVHHY; as outlined
previously.19 The peptides were selected based on the HLA class I
typing of the patient. After 14 days, these T cells were harvested and
tested for microbial contamination. T cells were prepared for
intravenous infusion by washing twice in normal saline then resus-
pended in 20ml normal saline for infusion.
Monitoring of CMV-speciﬁc T-cell immunity
CMV-speciﬁc T cells before and after adoptive therapy were assessed
for cellular phenotype and T-cell functionality. Intracellular cytokine
ﬂow cytometer assays, on PBMC or in vitro expanded T cells
were performed as previously described.19 CD8+ T cells were assessed
for cytolytic potential using ﬂuorescein isothiocyanate (FITC)-
conjugated anti-CD107a (BD Biosciences, Franklin Lakes, NJ, USA)
and for intracellular cytokine using PE-conjugated anti-IFN-γ or
AlexaFluor700-conjugated anti-IFN-γ (BD Biosciences). To assess
the phenotype of HLA-B7/TPRVTGGGAM and HLA-A1/
VTEHDTLLY MHC class I dextramer (Immudex, Copenhagen, Den-
mark) speciﬁc cells, PBMC was stained with PerCP-Cy5.5-conjugated
anti-CD8 (eBioscience, San Diego, CA, USA), PE-Cy7-conjugated
anti-CD4 (BD Biosciences), V450-conjugated anti-CD27 (BD Bios-
ciences), FITC-conjugated anti-CD45RA (BD Biosciences), PE-
conjugated anti-PD1 (BD Biosciences) and biotin-conjugated anti-
CD57 (BD Biosciences). All cell acquisitions were performed on a BD
Fortessa with FACS Diva software, and post-acquisition analysis was
performed using FlowJo software (TreeStar, Ashland, OR, USA).
CMV load monitoring
CMV DNA was extracted from plasma or serum samples and
quantitation of CMV viral load was performed by the importation
of a standard curve created using the Acrometrix CMV standard panel
(Life Technologies, Carlsbad, CA, USA) according to manufacturers’
instructions. Each concentration was tested triplicate. Inter-run
variance was corrected for by the inclusion of calibrators and controls
in each run.
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